Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of DWC202511 or DWC202512 on Enavogliflozin in Healthy Adults
NCT07213310Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 1 week and Area Under the Curve to the Last Measurable Concentration at 1 week. Started Nov 2025; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07213310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213310.